Targeting monocyte and macrophage subpopulations for immunotherapy: a patent review (2009 – 2013)

Bibliography

• Wynn TA, Chawla A, Pollard JW. Macrophage biology in development, homeostasis and disease. Nature 2013;496:445-55
   PubMed Web of Science ®Google Scholar
• Gordon S, Martinez FO. Alternative activation of macrophages: mechanism and functions. Immunity 2010;32:593-604
   PubMed Web of Science ®Google Scholar
• Sica A, Mantovani A. Macrophage plasticity and polarization: in vivo veritas. J Clin Invest 2012;122:787-95
   PubMed Web of Science ®Google Scholar
• Szanto A, Balint BL, Nagy ZS, et al. STAT6 transcription factor is a facilitator of the nuclear receptor PPARγ-regulated gene expression in macrophages and dendritic cells. Immunity 2010;33:699-712
   PubMed Web of Science ®Google Scholar
• Egawa M, Mukai K, Yoshikawa S, et al. Inflammatory monocytes recruited to allergic skin acquire an anti-inflammatory M2 phenotype via basophil-derived interleukin-4. Immunity 2013;38:570-80
   PubMed Web of Science ®Google Scholar
• Bajaña S, Herrera-González N, Narváez J, et al. Differential CD4(+) T-cell memory responses induced by two subsets of human monocyte-derived dendritic cells. Immunology 2007;122:381-93
   PubMedGoogle Scholar
• Randolph GJ, Sanchez-Schmitz G, Liebman RM, et al. The CD16(+) (FcgammaRIII(+)) subset of human monocytes preferentially becomes migratory dendritic cells in a model tissue setting. J Exp Med 2002;196:517-27
   PubMedGoogle Scholar
• Sánchez-Torres C, García-Romo GS. CD16+ and CD16− human blood monocyte subsets differentiate in vitro to dendritic cells with different abilities to stimulate CD4+ T cells. Int Immunol 2001;13:1571-81
   PubMedGoogle Scholar
• Schulz C, Gomez Perdiguero E, Chorro L, et al. A lineage of myeloid cells independent of Myb and hematopoietic stem cells. Science 2012;336:86-90
   PubMed Web of Science ®Google Scholar
• Jakubzick C, Gautier EL, Gibbings SL, et al. Minimal differentiation of classical monocytes as they survey steady-state tissues and transport antigen to lymph nodes. Immunity 2013;39:599-610
   PubMedGoogle Scholar
• Yona S, Kim KW, Wolf Y, et al. Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis. Immunity 2013;38:79-91
   PubMed Web of Science ®Google Scholar
• Davis MJ, Tsang TM, Qiu Y, et al. Macrophage M1/M2 polarization dynamically adapts to changes in cytokine microenvironments in Cryptococcus neoformans infection. mBio 2013;4:264-13
   PubMed Web of Science ®Google Scholar
• Khallou-Laschet J, Varthaman A, Fornasa G. Macrophage plasticity in experimental atherosclerosis. PLoS One 2010;5:e8852
   PubMed Web of Science ®Google Scholar
• Cros J, Cagnard N, Woollard K, et al. Human CD14dim monocytes patrol and sense nucleic acids and viruses via TLR7 and TLR8 receptors. Immunity 2010;33(3):1-12
   PubMedGoogle Scholar
• Geissmann F, Jung S, Littman DR. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity 2003;19:71-82
   PubMed Web of Science ®Google Scholar
• Ingersoll MA, Spanbroek R, Lottaz C, et al. Comparison of gene expression profiles between human and mouse monocyte subsets. Blood 2010;115:e10-19
   PubMed Web of Science ®Google Scholar
• Wong KL, Tai JJY, Wong WC, et al. Gene expression profiling reveals the defining features of the classical, intermediate, and nonclassical human monocyte subsets. Blood 2011;118:e16-31
   PubMed Web of Science ®Google Scholar
• Zawada AM, Rogacev KS, Rotter B, et al. SuperSAGE evidence for CD14++CD16+ monocytes as a third monocyte subset. Blood 2011;118:e50-61
   PubMed Web of Science ®Google Scholar
• Rogacev KS, Seiler S, Zawada AM, et al. CD14++CD16+ monocytes and cardiovascular outcome in patients with chronic kidney disease. Eur Heart J 2011;32:84-92
   PubMed Web of Science ®Google Scholar
• Cooper DL, Martin SG, Robinson JI, et al. FcγRIIIa expression on monocytes in rheumatoid arthritis: role in immune-complex stimulated TNF production and non-response to methotrexate therapy. PLoS One 2012;7:e28918
   PubMed Web of Science ®Google Scholar
• Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994;76:301-14
   PubMed Web of Science ®Google Scholar
• Auffray C, Fogg D, Garfa M, et al. Monitoring of blood vessels and tissues by a population of monocytes with patrolling behavior. Science 2007;317:666-70
   PubMed Web of Science ®Google Scholar
• Wong KL, Chen W, Balakrishnan T, et al. Susceptibility and response of human blood monocyte subsets to primary dengue virus infection. PLoS ONE 2012;7:e36435
   PubMedGoogle Scholar
• Zhang J-Y, Zou Z-S, Huang A, et al. Hyper-activated pro-inflammatory CD16 monocytes correlate with the severity of liver injury and fibrosis in patients with chronic hepatitis B. PLoS ONE 2011;6:e17484
   PubMedGoogle Scholar
• Serbina NV, Pamer EG. Monocyte emigration from bone marrow during bacterial infection requires signals mediated by chemokine receptor CCR2. Nat Immunol 2006;7:311-17
   PubMed Web of Science ®Google Scholar
• Peters W, Scott HM, Chambers HF, et al. Chemokine receptor 2 serves an early and essential role in resistance to Mycobacterium tuberculosis. Proc Natl Acad Sci USA 2001;98:7958-63
   PubMed Web of Science ®Google Scholar
• Zhong H, Yazdanbakhsh K. Differential control of Helios+/- Treg development by monocyte subsets through disparate inflammatory cytokines. Blood 2013;121:2494-502
   PubMedGoogle Scholar
• Philadelphia TCHO. Ex vivo-modified monocytes as local delivery vehicles to treat diseased arteries. WO2013071015; 2013
   Google Scholar
• Ouchi N, Kihara S, Arita Y, et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 2001;103:1057-63
   PubMed Web of Science ®Google Scholar
• Kollias A, Tsiotra PC, Ikonomidis I, et al. Adiponectin levels and expression of adiponectin receptors in isolated monocytes from overweight patients with coronary artery disease. Cardiovasc Diabetol 2011;10:14
   PubMed Web of Science ®Google Scholar
• Ohashi K, Parker JL, Ouchi N, et al. Adiponectin promotes macrophage polarization toward an anti-inflammatory phenotype. J Biol Chem 2010;285:6153-60
   PubMed Web of Science ®Google Scholar
• Cheng X, Folco EJ, Shimizu K, et al. Adiponectin induces pro-inflammatory programs in human macrophages and CD4+ T cells. J Biol Chem 2012;287:36896-904
   PubMedGoogle Scholar
• Neumeier M, Weigert J, Schäffler A, et al. Different effects of adiponectin isoforms in human monocytic cells. J Leukoc Biol 2006;79:803-8
   PubMed Web of Science ®Google Scholar
• Kadowaki T, Yamauchi T, Kubota N, et al. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 2006;116:1784-92
   PubMed Web of Science ®Google Scholar
• Wang Y, Lam KSL, Yau M-H, et al. Post-translational modifications of adiponectin: mechanisms and functional implications. Biochem J 2008;409:623-33
   PubMed Web of Science ®Google Scholar
• Lyakh LA, Koski GK, Young HA. Adenovirus type 5 vectors induce dendritic cell differentiation in human CD14+ monocytes cultured under serum-free conditions. Blood 2002;99:600-8
   PubMedGoogle Scholar
• Yeda Research And Development Co. Ltd. Human monocyte sub-population for treatment of central nervous system injury. WO2013088441; 2013
   Google Scholar
• Wisconsin Alumni Research Foundation. Generation of a novel type of anti-inflammatory macrophages for clinical use. WO2011025787; 2011
   Google Scholar
• Bomstein Y, Marder JB, Vitner K, et al. Features of skin-coincubated macrophages that promote recovery from spinal cord injury. J Neuroimmunol 2003;142:10-16
   PubMed Web of Science ®Google Scholar
• Rapalino O, Lazarov-Spiegler O, Agranov E, et al. Implantation of stimulated homologous macrophages results in partial recovery of paraplegic rats. Nat Med 1998;4:814-21
   PubMed Web of Science ®Google Scholar
• Yeda Research And Development Co., Ltd. Mononuclear phagocytes and their use to promote axonal regeneration. WO1998041220; 1998
   Google Scholar
• Knoller N, Auerbach G, Fulga V, et al. Clinical experience using incubated autologous macrophages as a treatment for complete spinal cord injury: phase I study results. J Neurosurg Spine 2005;3:173-81
   PubMed Web of Science ®Google Scholar
• Lammertse DP, Jones LAT, Charlifue SB, et al. Autologous incubated macrophage therapy in acute, complete spinal cord injury: results of the phase 2 randomized controlled multicenter trial. Spinal Cord 2012;50:661-71
   PubMed Web of Science ®Google Scholar
• Shechter R, London A, Varol C, et al. Infiltrating blood-derived macrophages are vital cells playing an anti-inflammatory role in recovery from spinal cord injury in mice. PLoS Med 2009;6:e1000113
   PubMed Web of Science ®Google Scholar
• Donnelly DJ, Longbrake EE, Shawler TM. Deficient CX3CR1 signaling promotes recovery after mouse spinal cord injury by limiting the recruitment and activation of Ly6Clo/iNOS+ macrophages. J Neurosci 2011;31:9910-22
   PubMedGoogle Scholar
• Nahrendorf M, Swirski FK, Aikawa E, et al. The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. J Exp Med 2007;204:3037-47
   PubMed Web of Science ®Google Scholar
• Kim J, Hematti P. Mesenchymal stem cell-educated macrophages: a novel type of alternatively activated macrophages. Exp Hematol 2009;37:1445-53
   PubMed Web of Science ®Google Scholar
• La Jolla Institute For Allergy And Immunology. Methods and uses of nur77 and nur77 agonists to modulate macrophages and monocytes, and treat inflammation, inflammatory disease, and cardiovascular disease. WO2011127288; 2011
   Google Scholar
• Pei L, Castrillo A, Chen M, et al. Induction of NR4A orphan nuclear receptor expression in macrophages in response to inflammatory stimuli. J Biol Chem 2005;280:29256-62
   PubMed Web of Science ®Google Scholar
• Pei L, Castrillo A, Tontonoz P. Regulation of macrophage inflammatory gene expression by the orphan nuclear receptor Nur77. Mol Endocrinol 2006;20:786-94
   PubMed Web of Science ®Google Scholar
• Bonta PI, van Tiel CM, Vos M, et al. Nuclear receptors Nur77, Nurr1, and NOR-1 expressed in atherosclerotic lesion macrophages reduce lipid loading and inflammatory responses. Arterioscler Thromb Vasc Biol 2006;26:2288-94
   PubMed Web of Science ®Google Scholar
• Hanna RN, Carlin LM, Hubbeling HG, et al. The transcription factor NR4A1 (Nur77) controls bone marrow differentiation and the survival of Ly6C− monocytes. Nat Immunol 2011;12:778-85
   PubMed Web of Science ®Google Scholar
• Hanna RN, Shaked I, Hubbeling HG, et al. NR4A1 (Nur77) deletion polarizes macrophages toward an inflammatory phenotype and increases atherosclerosis. Circ Res 2012;110:416-27
   PubMed Web of Science ®Google Scholar
• Hamers AAJ, Vos M, Rassam F, et al. Bone marrow-specific deficiency of nuclear receptor Nur77 enhances atherosclerosis. Circ Res 2012;110:428-38
   PubMed Web of Science ®Google Scholar
• Chao LC, Soto E, Hong C, et al. Bone marrow NR4A expression is not a dominant factor in the development of atherosclerosis or macrophage polarization in mice. J Lipid Res 2013;54:806-15
   PubMedGoogle Scholar
• Hamers AAJ, Uleman S, van Tiel CM, et al. Limited Role of Nuclear Receptor Nur77 in Escherichia coli-Induced Peritonitis. Infect Immun 2014;82:253-64
   PubMedGoogle Scholar
• Arkenbout EK, van Bragt M, Eldering E, et al. TR3 orphan receptor is expressed in vascular endothelial cells and mediates cell cycle arrest. Arterioscler Thromb Vasc Biol 2003;23:1535-40
   PubMed Web of Science ®Google Scholar
• de Waard V, Arkenbout EK, Vos M, et al. TR3 nuclear orphan receptor prevents cyclic stretch-induced proliferation of venous smooth muscle cells. Am J Pathol 2006;168:2027-35
   PubMed Web of Science ®Google Scholar
• Cheng Z, Völkers M, Din S, et al. Mitochondrial translocation of Nur77 mediates cardiomyocyte apoptosis. Eur Heart J 2011;32:2179-88
   PubMed Web of Science ®Google Scholar
• Zeng H, Qin L, Zhao D, et al. Orphan nuclear receptor TR3/Nur77 regulates VEGF-A–induced angiogenesis through its transcriptional activity. J Exp Med 2006;203:719-29
   PubMed Web of Science ®Google Scholar
• Lee S-O, Li X, Khan S, et al. Targeting NR4A1 (TR3) in cancer cells and tumors. Expert Opin Ther Targets 2011;15:195-206
   PubMed Web of Science ®Google Scholar
• Shah P, Sharifi B. Atherosclerosis inhibition via modulation of monocyte-macrophage phenotype using Apo-Ai Milano gene transfer. WO2012024309; 2012
   Google Scholar
• Franceschini G, Sirtori CR, Capurso A, et al. A-IMilano apoprotein. Decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family. J Clin Invest 1980;66:892-900
   PubMed Web of Science ®Google Scholar
• Sirtori CR, Calabresi L, Franceschini G, et al. Cardiovascular status of carriers of the apolipoprotein A-IMilano mutant: the Limone sul Garda Study. Circulation 2001;103(15):1949-54
   PubMedGoogle Scholar
• Weisgraber KH, Rall SC, Bersot TP, et al. Apolipoprotein A-IMilano. Detection of normal AI in affected subjects and evidence for a cysteine for arginine substitution in the variant AI. J Biol Chem 1983;258:2508-13
   PubMed Web of Science ®Google Scholar
• Parolini C, Chiesa G, Gong E, et al. Apolipoprotein AI and the molecular variant apoA-I Milano: evaluation of the antiatherogenic effects in knock-in mouse model. Atherosclerosis 2005;183:222-9
   PubMedGoogle Scholar
• Li D, Weng S, Yang B, et al. Inhibition of arterial thrombus formation by ApoA1 Milano. Arterioscler Thromb Vasc Biol 1999;19:378-83
   PubMed Web of Science ®Google Scholar
• Alexander ET, Weibel GL, Joshi MR, et al. macrophage reverse cholesterol transport in mice expressing ApoA-I Milano. Arterioscler Thromb Vasc Biol 2009;29:1496-501
   PubMed Web of Science ®Google Scholar
• Weibel GL, Alexander ET, Joshi MR. Wild-type ApoA-I and the Milano variant have similar abilities to stimulate cellular lipid mobilization and efflux. Arterioscler Thromb Vasc Biol 2007;27:2022-9
   PubMed Web of Science ®Google Scholar
• Shanghai 10th Peoples Hospital. Apolipoprotein A-I (ApoA-I) milano genetic medicine. CN102240405; 2011
   Google Scholar
• Cedars-Sinai Medical Center, City of Hope. Prevention And treatment of vascular disease with recombinant adeno-associated virus vectors encoding apolipoprotein A-I and apolipoprotein A-I Milano. WO2005097206; 2005
   Google Scholar
• The U.S.A., Department Of Health And Human Services, Baker IDI Heart & Diabetes Institute. Synthetic apoa-1 mimetic amphipathic peptides and methods of use thereof. WO2011066511; 2011
   Google Scholar
• Pfizer Inc. Recombinant apoa-1m from engineered bacteria. WO2013016428; 2012
   Google Scholar
• Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003;290:2292-300
   PubMed Web of Science ®Google Scholar
• Chinetti-Gbaguidi G, Baron M, Bouhlel MA, et al. Human atherosclerotic plaque alternative macrophages display low cholesterol handling but high phagocytosis because of distinct activities of the PPARγ and LXRα pathways. Circ Res 2011;108:985-95
   PubMed Web of Science ®Google Scholar
• Medbury HJ, James V, Ngo J, et al. Differing association of macrophage subsets with atherosclerotic plaque stability. Int Angiol 2013;32:74-84
   PubMedGoogle Scholar
• Board of Regents, The University of Texas System. Liposome-incorporated mepartricin. WO1989003677; 1989
   Google Scholar
• University of California. Liposome-encapsulated anti-viral composition and method. WO1989005152; 1989
   Google Scholar
• Moma Therapeutics. Implantable liposome embedded matrix composition, uses thereof, and polycaprolactone particles as scaffolds for tissue regeneration. WO2010060104; 2010
   Google Scholar
• Bioneer A/S. Cationic liposomal drug delivery system for specific targeting of human CD14+ monocytes in whole blood. WO2013135800; 2012
   Google Scholar
• Wagner T, Yu X. Monocyte-specific particulate delivery vehicle. WO2002078733; 2002
   Google Scholar
• Getts Consulting and Project Management. Modified immune-modulating particles. WO2012065153; 2011
   Google Scholar
• Danhier F, Ansorena E, Silva JM, et al. PLGA-based nanoparticles: an overview of biomedical applications. J Control Release 2012;161:505-22
   PubMed Web of Science ®Google Scholar
• Lu L, Peter SJ, Lyman MD, et al. In vitro and in vivo degradation of porous poly(DL-lactic-co-glycolic acid) foams. Biomaterials 2000;21:1837-45
   PubMed Web of Science ®Google Scholar
• Astete CE, Sabliov CM. Synthesis and characterization of PLGA nanoparticles. J Biomater Sci 2006;17:247-89
   PubMed Web of Science ®Google Scholar
• Getts DR, Terry RL, Getts MT. Therapeutic inflammatory monocyte modulation using immune-modifying microparticles. Sci Transl Med 2014;6:219ra7
   PubMed Web of Science ®Google Scholar
• Potteaux S, Gautier EL, Hutchison SB, et al. Suppressed monocyte recruitment drives macrophage removal from atherosclerotic plaques of Apoe–/– mice during disease regression. J Clin Invest 2011;121:2025-36
   PubMedGoogle Scholar
• Tacke F, Alvarez D, Kaplan TJ, et al. Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. J Clin Invest 2007;117:185-94
   PubMed Web of Science ®Google Scholar
• Karathanasis E, Geigerman CM, Parkos CA, et al. Selective targeting of nanocarriers to neutrophils and monocytes. Ann Biomed Eng 2009;37:1984-92
   PubMed Web of Science ®Google Scholar
• Lee KD, Nir S, Papahadjopoulos D. Quantitative analysis of liposome-cell interactions in vitro: rate constants of binding and endocytosis with suspension and adherent J774 cells and human monocytes. Biochemistry 1993;32:889-99
   PubMed Web of Science ®Google Scholar
• Filion MC, Phillips NC. Major limitations in the use of cationic liposomes for DNA delivery. Int J Pharm 1998;162:159-70
   Web of Science ®Google Scholar
• Jensen SS, Johansen PT, Zucker D. Whole blood targeting and activation of monocytes with TLR7 agonist formulated in cationic liposomes. J Immunother Cancer 2013;1:130
   Google Scholar
• Pires P, Simões S, Nir S, et al. Interaction of cationic liposomes and their DNA complexes with monocytic leukemia cells. Biochim Biophys Acta 1999;1418:71-84
   PubMed Web of Science ®Google Scholar
• Shi C, Pamer EG. Monocyte recruitment during infection and inflammation. Nat Rev Immunol 2011;11:762-74
   PubMed Web of Science ®Google Scholar
• Tsou C-L, Peters W, Si Y, et al. Critical roles for CCR2 and MCP-3 in monocyte mobilization from bone marrow and recruitment to inflammatory sites. J Clin Invest 2007;117:902-9
   PubMed Web of Science ®Google Scholar
• Jia T, Serbina NV, Brandl K, et al. Additive roles for MCP-1 and MCP-3 in CCR2-mediated recruitment of inflammatory monocytes during Listeria monocytogenes infection. J Immunol 2008;180(10):6846-53
   PubMed Web of Science ®Google Scholar
• Carlin LM, Stamatiades EG, Auffray C, et al. Nr4a1-dependent Ly6C(low) monocytes monitor endothelial cells and orchestrate their disposal. Cell 2013;153:362-75
   PubMed Web of Science ®Google Scholar
• Boehringer Ingelheim International GMBH. Novel and selective CCR2 antagonists. WO2013010839; 2013
   Google Scholar
• Pfizer Inc. Antibodies to ccr2. WO2010021697; 2009
   Google Scholar
• Boehringer Ingelheim International GMBH. Ccr2 antagonists and uses thereof. WO2011144501; 2011
   Google Scholar
• Paris 6 UPEMC. Ccr2 antagonist peptides. WO2013000922; 2012
   Google Scholar
• Boehringer Ingelheim International GMBH. Cx3cr1-binding polypeptides. WO2013130381; 2013
   Google Scholar
• Paris 6 UPEMC. Modulators of the cx3cr1 receptor and therapeutic uses thereof. WO2010079063; 2009
   Google Scholar
• Majmudar MD, Keliher EJ, Heidt T, et al. Monocyte-directed RNAi targeting CCR2 improves infarct healing in atherosclerosis-prone mice. Circulation 2013;127:2038-46
   PubMed Web of Science ®Google Scholar
• Leuschner F, Dutta P, Gorbatov R, et al. Therapeutic siRNA silencing in inflammatory monocytes in mice. Nat Biotechnol 2011;29:1005-10
   PubMed Web of Science ®Google Scholar
• Vergunst CE, Gerlag DM, Lopatinskaya L, et al. Modulation of CCR2 in rheumatoid arthritis: a double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum 2008;58:1931-9
   PubMed Web of Science ®Google Scholar
• D'Haese JG, Friess H, Ceyhan GO. Therapeutic potential of the chemokine-receptor duo fractalkine/CX3CR1: an update. Expert Opin Ther Targets 2012;16:613-18
   PubMed Web of Science ®Google Scholar
• Lionakis MS, Swamydas M, Fischer BG. CX3CR1-dependent renal macrophage survival promotes Candida control and host survival. J Clin Invest 2013;123:5035-51
   PubMed Web of Science ®Google Scholar
• Robbins CS, Hilgendorf I, Weber GF, et al. Local proliferation dominates lesional macrophage accumulation in atherosclerosis. Nat Med 2013;19:1166-72
   PubMed Web of Science ®Google Scholar
• Gautier EL, Ivanov S, Lesnik P, et al. Local apoptosis mediates clearance of macrophages from resolving inflammation in mice. Blood 2013;122:2714-22
   PubMed Web of Science ®Google Scholar
• Seok J, Warren HS, Cuenca AG, et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. PNAS 2013;110:3507-12
   PubMed Web of Science ®Google Scholar